Credit Suisse Group set a $142.00 target price on Puma Biotechnology (NASDAQ:PBYI) in a research note released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on PBYI. Royal Bank of Canada lowered their price target on Puma Biotechnology from $108.00 to $92.00 and set a sector perform rating on the stock in a research note on Friday, November 10th. They noted that the move was a valuation call. Citigroup restated a buy rating and set a $156.00 price target (up from $114.00) on shares of Puma Biotechnology in a research note on Thursday, October 5th. Leerink Swann boosted their price target on Puma Biotechnology to $140.00 and gave the company an outperform rating in a research note on Friday, October 27th. Bank of America restated a buy rating and set a $135.00 price target (up from $117.00) on shares of Puma Biotechnology in a research note on Monday, October 9th. Finally, BidaskClub upgraded Puma Biotechnology from a buy rating to a strong-buy rating in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Puma Biotechnology currently has an average rating of Buy and an average target price of $130.67.
Puma Biotechnology (NASDAQ PBYI) opened at $88.25 on Monday. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90. The stock has a market capitalization of $3,310.00, a PE ratio of -10.78 and a beta of 0.72.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the prior year, the firm earned ($1.11) earnings per share. equities analysts forecast that Puma Biotechnology will post -8.17 EPS for the current fiscal year.
In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of Puma Biotechnology stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 21.10% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in PBYI. Schwab Charles Investment Management Inc. boosted its holdings in shares of Puma Biotechnology by 3.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 123,380 shares of the biopharmaceutical company’s stock worth $10,784,000 after acquiring an additional 4,068 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Puma Biotechnology by 1.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 136,297 shares of the biopharmaceutical company’s stock worth $11,912,000 after acquiring an additional 2,072 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Puma Biotechnology by 12.8% in the 2nd quarter. Legal & General Group Plc now owns 10,490 shares of the biopharmaceutical company’s stock worth $918,000 after acquiring an additional 1,193 shares in the last quarter. Prudential Financial Inc. acquired a new position in Puma Biotechnology during the 2nd quarter worth $302,000. Finally, Principal Financial Group Inc. acquired a new position in Puma Biotechnology during the 2nd quarter worth $460,000. 96.00% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Credit Suisse Group Analysts Give Puma Biotechnology (PBYI) a $142.00 Price Target” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://transcriptdaily.com/2018/01/19/credit-suisse-group-analysts-give-puma-biotechnology-pbyi-a-142-00-price-target.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.